Mengjuan Yuan
Chongqing, 400016, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer.
Journal: Iranian journal of public health
Published: March 10, 2022
Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM.
Journal: British journal of cancer
Published: March 16, 2020
Phospholipase C (PLC)ε Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line.
Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: June 16, 2019
Simvastatin delays castration‑resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin‑1.
Journal: International journal of oncology
Published: November 27, 2018
PLCε promotes urinary bladder cancer cells proliferation through STAT3/LDHA pathway‑mediated glycolysis.
Journal: Oncology reports
Published: October 09, 2018
Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Journal: Oncology reports
Published: October 08, 2018
[Corrigendum] Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Journal: Oncology reports
Published: October 08, 2018
PLCε knockdown overcomes drug resistance to androgen receptor antagonist in castration-resistant prostate cancer by suppressing the wnt3a/β-catenin pathway.
Journal: Journal of cellular physiology
Published: August 04, 2018
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Journal: International journal of oncology
Published: November 21, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026